Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

Depression Clinical Trial

Official title:

Pharmacogenomic Study to Predict Antidepressant Responsiveness in Depressed Patients

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT00817375
• Other study ID #: 2003-01-12
• Status: Recruiting
• Phase: N/A
• First received: January 5, 2009
• Last updated: December 30, 2015
• Start date: February 2003
• Est. completion date: December 2018

Study information

• Verified date: December 2015
• Source: Samsung Medical Center
• Contact: JungShil Back, B/Sc.
• Phone: 82-2-3410-0946
• Email: jungshil.back[@]sbri.co.kr
• Is FDA regulated: No
• Health authority: South Korea: Institutional Review Board
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to determine whether pharmacogenomic study predict antidepressant responsiveness in advance before the appearance of the drug effects until 4~6 weeks after drug administration.

Description:

The purpose of this study is

1. to determine whether genomic effects on antidepressant response differed by class of drug,

2. whether genomic differences between drug responders and nonresponders predict the response of antidepressant and

3. to construct the prediction model for antidepressant treatment in order to aid to select the their genetically matching drugs.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 1000
• Est. completion date: December 2018
• Est. primary completion date: December 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 19 Years to 89 Years

Eligibility

Inclusion Criteria:

1. Eligible patients were enrolled in the clinical trials program of hte Samsung Medical Center Geropsychiatry and Affective Disorder Clinics(Seoul, Korea). They received a semistructured diagnostic interview, the Samsung Psychiatric Evaluation Schedule. The affective disorder section of the Samsung Psychiatric Evaluation Schedule uses the Korean version of the structured clinical interview for the diagnostic and statistical manual of mental disorders, Fourth edition.

2. interview with one more patient's family member for objective diagnosis and final diagnosis decision by agreements of two more psychiatric physicians

Exclusion Criteria:

1. received psychotropic medication within 2 weeks of the study or fluoxetine within 4 weeks

2. potential study participants for pregnancy, significant medical conditions, abnormal laboratory baseline values, unstable psychiatric features(eg.suicidal), history of alcohol of drug dependence, seizures, head trauma with loss of consciousness, neurological illness, or concomitant Axis I psychiatric disorder.

Study Design

Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Treatment

Related Conditions & MeSH terms

• Adverse Reaction to Drug
• Depression
• Drug-Related Side Effects and Adverse Reactions

Intervention

Drug:
• SSRI treated group
Antidepressant administration of SSRI class for 6 weeks under therapeutic dose
• non-SSRI treated group
Antidepressant administration of non-SSRI class for 6 weeks under therapeutic dose

Locations

Country	Name	City	State
Korea, Republic of	Samsung Medical Center	Kangnam	Seoul

Sponsors (1)

Lead Sponsor	Collaborator
Samsung Medical Center

Country where clinical trial is conducted

Korea, Republic of, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Antidepressant Response at 2,4,6 weeks A/E monitoring at 1,2,4,6 weeks		6 weeks	Yes
Secondary	Biological value at 0 and 6 weeks		6weeks	Yes